Synergestic roles of SRSF2 and RUNX1 in blood cell development and pathology

SRSF2 和 RUNX1 在血细胞发育和病理学中的协同作用

• 批准号: 8647698
• 负责人: XIANG-DONG FU
• 金额: $ 47.06万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-16 至 2018-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8647698
• 关键词: Affect; Alternative Splicing; Animal Model; Basic Science; Biochemical; Biological Assay; Biological Process; Blood Cells; Bone Marrow Cells; Bone Marrow Diseases; CD34 gene; Cell Differentiation process; Cell Proliferation; Cell model; Cells; ChIP-seq; Chemicals; Data; Development; Disease; Disease model; Dysmyelopoietic Syndromes; Event; Failure; Foundations; Frequencies; Functional disorder; Gene Expression; Gene Mutation; Genes; Genetic; Genetic Transcription; Genome; Genomics; Goals; Hematopoiesis; Hematopoietic; Human; Intervention; Large-Scale Sequencing; Lead; Link; Messenger RNA; Molecular; Mutate; Mutation; Pancytopenia; Pathology; Pathway interactions; Patients; Phenotype; Play; Proline; Property; Protein Isoforms; Quality of life; RNA Binding; RNA Splicing; RUNX1 gene; Research; Research Design; Role; Sampling; Series; Site; Stem cells; Sum; Syndrome; Technology; Testing; Transcription Elongation; Transcriptional Activation; Translational Research; Umbilical Cord Blood; base; disease phenotype; effective therapy; experience; gene function; insight; mouse model; mutant; novel; novel therapeutics; outcome forecast; promoter; public health relevance; screening; stem; tool; transcription factor; transcriptome sequencing

Project Summary/Abstract Recent large-scale sequencing efforts have revealed prevalent mutations in splicing factor-encoded genes in bone marrow failure diseases, such as myelodysplastic syndromes (MDS) and related disorders. In particular, mutations in the splicing factor SRSF2 were significantly associated with mutations of RUNX1, a transcription factor with an established role in various blood cell disorders. These findings suggest a critical role of these factors in blood cell pathology, likely through their synergistic effects in regulated gene expression, and potentiate the development of new therapeutics against specific types of bone marrow failure disorders. The goal of this proposal is to establish the causal role of SRSF2 mutations and their genetic interactions with RUNX1 in bone marrow disorders. Our labs have been systematically pursuing the biological function and regulatory mechanisms of RUNX1 (Zhang lab) and SRSF2 (Fu lab) for many years. Recently, our research has led to novel insights into the mechanism of these genes in regulated gene expression. We have an established collaborative record, and our combined expertise is ideally suited to pursue the disease mechanism and develop novel therapeutic strategies through a concerted effort. Therefore, we propose to join forces to attack the problem under the following specific aims: 1) Establish causal mutations of SRSF2 and RUNX1 in MDS. We hypothesize that the mutations synergistically promote abnormal blood cell proliferation and development. 2) Understand the impact of the Proline 95 mutations on the functional properties of SRSF2. We hypothesize that MDS-associated mutations in SRSF2 may have altered the function of SRSF2 to affect specific splicing and/or transcription events that are critical for the development of blood cells. 3) Define critical molecular pathways underlying the disease phenotype. We hypothesize that mutations in these genes cause specific changes in regulated gene expression to favor disease development. We propose to define the altered molecular pathways using both cells isolated from animal models and human patient samples. In sum, we design the research through testing key hypotheses by using the latest genetic and genomic approaches. This proposal takes full advantage of our many years of effort and experience in basic and translational research. The studies are expected to provide valuable insights into the pathology of SRSF2 and RUNX1 mutation related bone marrow failure diseases, which will eventually benefit patients by facilitating the development of pathway directed chemical screening strategies.

项目摘要/摘要 最近的大规模测序工作揭示了剪接因子编码的普遍突变 骨髓衰竭疾病中的基因，例如骨髓增生综合征（MDS）和相关 疾病。特别是，剪接因子SRSF2中的突变与 Runx1的突变，这是一种在各种血细胞疾病中既有作用的转录因子。 这些发现表明，这些因素在血细胞病理学中的关键作用，可能是通过它们的 在调节基因表达中的协同作用，并增强新疗法的发展 针对特定类型的骨髓衰竭障碍。该提议的目的是建立 SRSF2突变的因果作用及其在骨髓疾病中与Runx1的遗传相互作用。 我们的实验室一直在系统地追求生物学功能和调节机制 Runx1（Zhang Lab）和SRSF2（FU实验室）多年。最近，我们的研究导致了新颖 在调节基因表达中对这些基因的机制的见解。我们已经建立了 协作记录和我们的综合专业知识非常适合追求疾病机制 并通过一致的努力制定新颖的治疗策略。因此，我们建议加入 在以下特定目的下攻击问题的力量：1）建立SRSF2的因果突变 和MDS中的Runx1。我们假设突变协同促进异常血细胞 扩散和发展。 2）了解脯氨酸95突变对功能的影响 SRSF2的属性。我们假设SRSF2中与MDS相关的突变可能改变了 SRSF2的功能影响特定的剪接和/或转录事件，这对于对 血细胞的发展。 3）定义疾病表型基础的关键分子途径。 我们假设这些基因中的突变导致调节基因表达的特定变化 有利于疾病发展。我们建议使用两个细胞来定义改变的分子途径 从动物模型和人类患者样本中分离出来。总而言之，我们通过 通过使用最新的遗传和基因组方法来检验关键假设。该提议满足 我们在基本和转化研究方面的多年努力和经验的优势。研究 期望对SRSF2和RUNX1突变相关的病理提供有价值的见解 骨髓衰竭疾病，最终将通过促进发展 途径指示化学筛选策略。